Stock Martket BSE » Stock Tips

Free Day Trading Tips – 08 Nov 2011

admin — Tue, 08 Nov 2011 03:47:16 +0000

Sell REI Agro at Rs 22.2-22.5, Stop Loss at Rs 22.8, Target at Rs 20.8-21.7 Buy Ambuja cement at Rs 159-160.2, Stop Loss at Rs 158.2, Target at Rs 162.3-165.6 Related posts:Free Intraday Tips – 3 Nov 2011 Free Day Trading Tips – 05 Sept 2011 Free Day Trading Tips – 17 May 2011 Related posts:

Free Day Trading Tips – 12 August 2011

admin — Fri, 12 Aug 2011 04:09:56 +0000

Buy RCF around Rs 81.30-84.30, stop loss Rs 79.40, book profit at Rs 89.10-96.90 Sell Crompton Greaves around Rs 148.20-145.90, stop loss Rs 149.30, cover short at Rs 142.50-136.70 Related posts:Free Intraday Stock Tips – 01 April 2010 Free Day Trading Tips – 29 March 2011 Free Intraday Stock Tips – 18 May 2010 Related posts:

V.S.T Tillers Tractors – short Term Investment

admin — Fri, 08 Jul 2011 13:22:38 +0000

BSE : 531266‎

CMP : 548.00

V.S.T Tillers Tractors Ltd (VTTL) was incorporated in the year 1967 in Bangalore, India. It was promoted by the V.S.T Group, a well known business house in South India, in technical collaboration and joint venture with Mitsubishi Heavy Industries and Mitsubishi Corporation, Japan for the manufacture of Power Tillers and Diesel Engines. The plant went into production in the year 1970.

The manufacturing plant is located in Whitefield Industrial area near Bangalore. It has 75,000 Sq. mtrs. of land and a built up area of 15,000 Sq. mtrs (approx). The Manufacturing capacity of the company, presently is 25,000 Power Tillers, 32,000 Engines and 5000 Tractors. This capacity can be enhanced upto 30% within a period of 6 to 8 months.

Company’s financials are strong with healthy balance sheet. The company delivered strong growth during FY06-11 with revenues CAGR of 27%. Its net profit CAGR was of 44%. EBITDA margins also expanded from 10.6% in FY06 to 16% in FY11. The company has strong balance sheet with net cash & cash equivalent to the tune of Rs 47 crore as on March 11.

VST Tillers Tractors Q4FY11 (YoY) net sales stood up 25% at Rs 129.3 crore vs Rs 103.8 crore, total expenditure stood up 29% at Rs 110 crore vs Rs 85 crore, EBITDA was flat at Rs 19.5 crore, EBITDA margins stood at 15% vs 19%, other income stood up more than double at Rs 2.93 crore vs Rs 1.4 crore and PAT stood at Rs 14.6 crore vs Rs 15 crore.

For FY11, its net sales stood up 23% at Rs 425 crore vs Rs 345 crore, total expenditure stood up 26% at Rs 360 crore vs Rs 285 crore, EBITDA stood up 9% at Rs 68 crore vs Rs 62.3 crore, EBITDA margins stood at 16% vs 18%, other income was up more than double at Rs 5.97 crore vs Rs 2.8 crore and PAT stood up 9% at Rs 46.2 crore vs Rs 42.33 crore.

Assam Company – Stock To Watch

admin — Tue, 05 Jul 2011 13:10:18 +0000

Assam Company India Limited is a group company comprising of professional companies engaged in multifaceted activities like Tea plantation, Oil & Gas exploration, production & supply, Road Transportation etc., and a heritage company since 1839.

Assam Company is one of fewest heritage companies in India serving to the development of industries over 165 year. It is the first tea plantation company in India started its tea garden in North East India in 1839. Assam Company is the first company to explore oil in Assam in the year 1889. It is indeed a story that the engineers supervising the wood felling and carrying through elephants, found mark of oil on the feet of the elephants. They reached the spot and asked the laborers to dig saying “Dig Boy, Dig”. In fact, this was phenomenally known as Digboi, the oldest Well of the country located in Upper Assam. Assam Company is the only non-government company that has been exploring oil in north east India and desires to expand its exploration in the basin of Bay of Bengal.

Africa tea output is down by 35 m kg this year. Low Arican output is going to aid Indian producers. Drop in African production is culminating into higher prices going forward. It has triggered off big buying from Egypt and UK. Shortage is likely to go upto $ 50-55 million in Africa.

Tea prices have gone up by Rs 10-15/kg. Rains may hit production. Further increase in tea prices is likely. Assam Company is looking at restructuring outstanding FCCBs. Its FCCBs worth $ 32 million will mature in November. Promoters hold 51.18% stake in the company

VIP Industries – Stocks To Watch

admin — Tue, 05 Jul 2011 13:06:16 +0000

VIP Industries stock is constantly hitting new highs. Declining polymer prices may impact the bottomline of the company. Soft luggage space is a major revenue driver for the company. Currency fluctuations is also a factor. Plastic prices are down by about 15%. Crude correction is likely to impact positively to the company.

A reduction of 2-3% in costs on prices of plastic is coming down. Softening of aluminum and steel costs will have positive impact. VIP Industries has market share of 21% in Qatar. The company is eyeing 20% growth in sales. It is planning to ramp up production in 3 production plants in India.

VIP Industries is expecting the margins to be good. It sees 65% of the business from soft luggage and sees 35% growth in margins in both soft and hard luggage.

Bharati Shipyard – Short Term Investment

admin — Fri, 01 Jul 2011 13:17:46 +0000

Bharati Shipyard Ltd is the foremost privately operated shipyard in terms of building facilities in India. BSL has earned its reputation by constructing a large array of specialized sophisticated vessels for diverse offshore, coastal and the marine market sectors. BSL product range includes highly maneuverable and power packed offshore vessels including AHTS, PSV’s and MSV’s of varying bollard pulls, Tractor and ASD tugs, state of the art dredgers, deep sea fishing vessels, cargo and container ships, tankers and Ro- Ro Vessels

The company has order book worries as on March 31, 2011. Its total order book has come down 9% at Rs 4635 crore vs Rs 5076 crore. Order book pending execution has halved to Rs 1,000 crore vs Rs 2252 crore.

Bharati Shipyard Q4FY11 (YoY) total revenues stood up 25% at Rs 441 crore vs Rs 352 crore, which includes subsidy revenue of Rs 94 crore vs Rs 25 crore and PAT stood up 10% at Rs 39.23 crore vs Rs 35.6 crore. EBITDA stood up 91% at Rs 157 crore vs Rs 82 crore, EBITDA margins were at 36% vs 23%. Its interest costs stood up almost 4 times at Rs 93 crore vs Rs 24 crore.

For FY11 (YoY), its total revenues stood up 17% at Rs 1581 crore vs Rs 1352 crore, owing to subsidy revenue at Rs 211 crore vs Rs 84 crore, EBITDA stood up 46% at Rs 465 crore vs Rs 319 crore, EBITDA margins stood at 29% vs 24%, interest cost was up almost 2.8 times at Rs 274 crore vs Rs 96 crore and PAT stood down 19% at Rs 113 crore vs Rs 139 crore.

Buy Indoco Remedies

admin — Tue, 24 May 2011 02:41:55 +0000

Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in India. Indoco has a strong international presence in the Regulated and Emerging markets. The Company is striving to place itself on a strong promising path by expanding its business strategically, strengthening its manufacturing facilities and enhancing capabilities across the organization. The Company is looking at various opportunities in untapped markets and association with business partners in the global markets to boost its revenues.

India is the world’s third largest producer of pharmaceuticals by volume, accounting for around 8% of global production. In value terms, production accounts for around 1.5% of the world total and stands 14th in terms of value.The Indian healthcare sector is expected reach US$ 280 billion by 2020, according to a report by an industry body.

The performances of some of Indoco’s main products have shown
a very good trend in this quarter and those products are Cyclopam tablets, Sensodent-K & Sensodent-KF for Dental, Karvol Plus capsules for respiratory, Clamcheck 625 mg tablets, those are antiinfective, Nosic tablets for gastrointestinal, and other ophthalmic products such as Irivisc, Macuchek, and Irimist.

During the fourth quarter ended March 31, the revenues from
domestic formulations business were marginally higher at Rs.722.3 Million as compared to Rs.717.5 Million over the same quarter last year. The revenues from API domestic business were higher by 53% at Rs.42.7 Million compared to Rs.28 Million. As regard the international business the international business grew overall by 28% at Rs.439.4 Million compared to Rs.343.2 Million over the same quarter for the previous year. The API export did well with a growth of 30% at Rs.40.3 Million compared to Rs.31 Million

Presently, the stock is trading at Rs 423 which is at a consolidated PE
of 7.97x and 6.48x to its FY12E and FY13E EPS of Rs 53.03 and
Rs.65.28 respectively.

Maruti Suzuki India – Stock Investment

admin — Sat, 02 Apr 2011 01:55:00 +0000

Maruti Suzuki India Limited (MSIL, formerly Maruti Udyog Limited), a subsidiary of Suzuki Motor Corporation of Japan, is India’s largest passenger car company, accounting for majority of the domestic car market.

Market leader in passenger cars – Maruti continues to hold dominant position in the passenger car segment with a 51% market share. We expect Maruti to maintain its domestic market leadership in passenger cars, especially in small and compact cars on the back of its strong product mix, efficient marketing strategies & widespread distribution network.

Suzuki launched its priciest offering in the sedan segment in India, Kizashi, in the month of February. Also it plans to come out with refreshes of its current models.

The company, in the past few quarters, has seen profits take a hit on account of rising input costs. Rise in interest rates has raised concerns about the consequent impact it is likely to have on sales volumes going forward. However, one must note that these are issues plaguing the auto sector as a whole and not Maruti in particular. As long as the India growth story remains intact, Maruti should see strong growth in car sales going forward. Further, the Japanese tsunami and earthquake has raised some more fears. One is the likely impact on account of shortage of auto components. Second is the appreciation of the Yen which is expected to put some pressure on margins. As a result, the stock has taken a beating in recent times. However, we believe that these are short term concerns, and the recent fall in prices mean that investors can lap up this stock for the long term potential that it holds at attractive prices. With point to point returns of 30% from a 2-3 year perspective, Maruti becomes a good bet for long term investors.

Debt to equity ratio: A highly leveraged business is the first to get hit during times of economic downturn, as companies have to consistently pay interest costs, despite lower profitability.

Liquidity: The average daily trading volumes of Maruti�s stock over the past 52 weeks stand at around 84,000 shares, which is a tad on the lower side. Hence, we assign a high risk rating of 3.

Dividend payout: A stable dividend history inspires confidence in the management’s intentions of rewarding shareholders. Maruti�s average payout ratio was around 8% in the last five years, which is on the lower side. Thus, we have assigned a high risk rating of 2 to the stock on this parameter.

Buy Glenmark Pharma

admin — Wed, 30 Mar 2011 02:26:38 +0000

Base business to grow over 18% CAGR:

We expect robust growth in base business (18% CAGR growth over FY10-13E) driven by growth in US generics (18.2% CAGR), Latam business (19.4% CAGR over FY10-13E) & domestic formulation business (18.4% CAGR over FY10-13E). The growth in US market can be attributed to growth in high margin derma products, hormonal products & others. Out of the 22 ANDAs filed for derma products, the company has approval of 18 ANDAs. Other opportunities in US market mainly include Oxycodone, Cutivate, & calcipotriene. Domestic market is expected to grow mainly on the back of new launches in key therapeutic segments viz respiratory, dermatology & anti-infectives. Completion of successful restructuring for Brazilian operations to add to the growth on Latam business.

EBITDA margins to improve by 160bps to 27.4% in FY12:

Company recently received an USFDA approval for Norethindrone & Ethinyl Estradiol tablets which marks company’s fourth entry into hormonal product portfolio & third in oral contraceptive segment. Company’s total pipeline for these products is worth ~ USD 141mn (IMS Health, Dec 2010). These products are very high margin products & presence of few players leads to higher profit realization.

Attractive First to File opportunity :

The company has a total of 11 Para IV (Mkt size – USD 6.8bn) of which the company has sole FTF (Mkt size – USD 1.6bn) opportunities on four products. Out of the four products, Malarone & Cutivate are expected to be launched in Q3FY12 & Q1FY12 respectively. This brings into account NPS/share of Rs 2 & 1.2 respectively for the company. Being FTF player it would be entitled to an exclusivity of 180 days.

R&D progress on track:

The company has total of 10 molecules in pipeline out of which two are in-licensed & one-out licensed. NCE viz Crofelemer (Mkt size – USD 80mn) & GRC15300 (USD 9bn) are progressing well and the launch is expected to happen in Q4FY12 & post FY15 respectively. This brings in NPV/share of Rs 25 & 22 respectively. Also recently the company’s NCE GRC-17536 got approval for human trials in Europe for multiple indications.

Free Day Trading Tips – 29 March 2011

admin — Tue, 29 Mar 2011 01:59:18 +0000

Buy SREI Infrastructure Finance at CMP Rs 43.95, Stop Loss: 42.25, Target 48

Buy Canara Bank at Rs 622.45, stop loss Rs 600, target Rs 660

Buy Chennai Petro at Rs 212.50 and on dips to Rs 208, stop loss Rs 200, target Rs 235

Buy Crompton Greaves at Rs 268.20 and Bank Of Baroda at Rs 927.90. Up side potential 4%.

Buy Mundra Port at Rs 137.95 and on dips to Rs 135, target Rs 145, stop loss Rs 132

Buy Kalpataru Power initially above Rs 123 and then on dips to Rs 118, target Rs 140, closing stop loss Rs 112